Related Experiment Videos
[Malignant pleural mesothelioma in 1997]
J R Viallat1, C Boutin, S Kasseyet
1Institut Paoli-Calmettes, Marseille.
Schweizerische Medizinische Wochenschrift
|January 24, 1998
Summary
Malignant pleural mesothelioma treatment varies by stage. Early stages benefit from immunotherapy, while advanced stages show better outcomes with surgery and updated TNM staging, similar to lung cancer prognoses.
Area of Science:
- Oncology
- Pulmonology
- Pathology
Context:
- Review of recent data on malignant pleural mesothelioma.
- Incorporation of the French 1996 INSERM report findings.
- Inclusion of a mineralogic study on anthracotic parietal pleura.
Purpose:
- To review current data and classifications for malignant pleural mesothelioma.
- To evaluate the efficacy of different treatment modalities.
- To highlight the importance of the new TNM staging system.
Summary:
- Intrapleural immunotherapy shows promise for early-stage mesothelioma.
- Radiotherapy has limited efficacy in advanced stages.
- Surgical series with the new TNM staging report improved survival rates.
- Malignant pleural mesothelioma prognosis is stage-dependent, with N- stages offering prolonged survival.
Impact:
- Provides an updated overview of malignant pleural mesothelioma management.
- Emphasizes the significance of accurate staging for treatment decisions.
- Suggests potential therapeutic strategies based on disease stage.